natgillin/translations-raw huggingface dataset:
A study was also carried out in 19 children aged between three and 15 years, where some improvements were seen in measurements relating to the heart and arteries.
Izvedli so tudi študijo pri 19 otrocih, starih od tri do 15 let, v kateri so opazili določeno izboljšanje pri parametrih, povezanih s srcem in arterijami.
A study was also carried out with the film-coated tablets in 19 children aged between three and 15 years.
Študija s filmsko obloženimi tabletami je bila izvedena tudi pri 19 otrocih, starih od tri do 15 let.
A study was also performed in seven children with PNH who had had at least one transfusion in the previous two years.
Izvedli so tudi študijo pri sedmih otrocih s to boleznijo, ki so v zadnjih dveh letih prejeli vsaj eno transfuzijo.
A study will be conducted to investigate this.
To bodo raziskali v raziskavi.
A study with peginterferon alfa–2a in treatment experienced patients gave consistent results as compared to the study P05101 (see section 4.4).
Rezultati iz študije s peginterferonom alfa-2b pri že zdravljenih bolnikih so bili skladni z rezultati iz študije P05101 (glejte poglavje 4.4).
A subcutaneous dose of 5 mg of Omnitrope powder and solvent for solution for injection in healthy adults results in plasma Cmax values of 71 ± 24 µg/l (mean ± SD) and median tmax value of 4 hours (range 2-8 hours), respectively.
Po subkutani uporabi 5 mg zdravila Omnitrope prašek in vehikel za raztopino za injiciranje pri zdravih odraslih je Cmax 71 ± 24 μg/l (srednja vrednost ± SD) in mediana tmax 4 ure (razpon 2 – 8 ur).
A subcutaneous injection of 50 mg golimumab to healthy subjects produced a mean  standard deviation maximum serum concentration (Cmax) of 3.1  1.4 g/mL.
S subkutanim injiciranjem 50 mg golimumaba zdravim preiskovancem so dosegli naslednjo srednjo vrednost ± standardno deviacijo največje serumske koncentracije zdravila (Cmax): 3,1 ± 1,4 g/ml.
A subcutaneous neonatal/juvenile toxicity study performed in rats 7-55 days of age resulted in a NOAEL of 10mg/kg/day.
V študiji toksičnosti subkutanih odmerkov, opravljeni pri novoskotenih/mladih podganah, starih od 7 do 55 dni, je bila vrednost NOAEL 10 mg/kg/dan.
a Subgroup analysis for patients on additional background of metformin (FAS, LOCF)
a Analiza pri podskupinah bolnikov ob dodatni prisotnosti metformina (FAS, LOCF)
a Subgroup analysis of full analysis set (FAS) for patients on additional background of metformin - Completers using last observation carried forward (LOCF) prior to glycaemic rescue therapy
a Niz celotne analize (FAS, full analysis set) podskupine bolnikov ob prisotnosti metformina, ki so študijo končali, z uporabo zadnjega opazovanja prenesenega naprej (LOCF) pred uporabo reševalnega zdravljenja za ureditev glikemije
A subgroup analysis of KEYNOTE-006 in patients who were BRAF wild type (n=525; 63%), BRAF mutant without prior BRAF treatment (n=163; 20%) and BRAF mutant with prior BRAF treatment (n=139; 17%) was performed.
V okviru KEYNOTE-006 je bila opravljena analiza podskupin bolnikov z divjim tipom BRAF (n = 525; 63 %), z mutacijo BRAF in brez predhodnega BRAF zdravljenja (n = 163; 20 %) ter z mutacijo BRAF in predhodnim BRAF zdravljenjem (n = 139; 17 %).
A subgroup of patients with baseline creatinine clearance between 50 and 60 ml/min, receiving once daily dosing, had a 2 – 4-fold increase in tenofovir exposure and worsening renal function.
Podskupina bolnikov z začetno vrednostjo očistka kreatinina med 50 in 60 ml/min, ki so ji zdravilo odmerjali enkrat dnevno, je imela 2-4-kratno povečanje izpostavljenosti tenofovirju in poslabšanje delovanja ledvic.
A subject is classified as “positive” or “negative” based on the brain amyloid plaque load (BAPL) score (Table 2) which is derived from RCTU scores in the four brain regions (Table 1).
Preiskovanec je klasificiran kot "pozitiven" ali "negativen" na osnovi ocene odlaganja amiloidnih leh v možganih (brain amyloid plaque load – BAPL) (Tabela 2), ki je izpeljana iz ocen RCTU v štirih regijah v možganih (Tabela 1).
A subject with multiple occurrence of an adverse drug reaction (ADR) is counted only once in that ADR category.
Oseba, pri kateri se je neželeni učinek zdravila večkrat ponovil, je za to kategorijo pogostnosti šteta samo enkrat.
A subject with multiple occurrences of an ADR is counted only once in that ADR category.
Oseba, pri kateri se je neželeni učinek večkrat ponovil, je za to kategorijo pogostnosti šteta samo enkrat.
a Subjects achieving clinical success (Clinical Response of “Cure” or “Improved”) and microbiological success (pathogen–level response of “Eradicated” or “Presumed Eradicated”) are classified as overall therapeutic success.
a Bolniki, pri katerih pride do kliničnega uspeha (klinični odziv je “ozdravitev” ali “izboljšanje”) in do mikrobiološkega uspeha (odziv s stopnjo prisotnosti patogenov “izkoreninjen” ali “domnevno izkoreninjen”), so opredeljeni kot skupni terapevtski uspeh.
a Subjects were from ITT population and received at least one dose of study drug in Study 1 or 2 b Each PDQ assessment required subjects to have had vaginal intercourse in the 3 months prior to completion c Higher scores represent worse symptoms
a Osebe so bile iz populacije ITT in so prejele vsaj en odmerek študijskega zdravila v študiji 1 ali 2 b Pri vsaki oceni PDQ se je od osebe zahtevalo, da ima v 3 mesecih pred izpolnitvijo vaginalni spolni odnos c Višji rezultati predstavljajo slabše simptome
A subject’s actual body weight at initiation of therapy should be used to calculate dose.
Za izračun odmerka morate uporabiti bolnikovo dejansko telesno maso na začetku zdravljenja.
A subsequent analysis of the duration of overall survival, carried out with a median follow-up duration of 60 months, confirmed the benefit of R-CHOP over CHOP treatment (p=0.0071), representing a risk reduction of 32 %.
Nadaljnja analiza trajanja celokupnega preživetja, ki so jo izvedli po medianem sledenju 60 mesecev, je potrdila prednost zdravljenja z R-CHOP pred CHOP (p = 0,0071), kar pomeni zmanjšanje tveganja za dogodke za 32 %.
A subsequent pack is started immediately after finishing the previous pack, without a break in daily tablet intake and irrespective of presence or absence of withdrawal bleeding.
Tablete iz naslednjega omota naj začne ženska jemati takoj, ko konča s prejšnjim, brez premora v vsakodnevnem jemanju tablet in neodvisno od tega, ali ima odtegnitveno krvavitev ali ne.
A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate.
Pri nekaterih od teh bolnikov so se simptomi ponovili ob ponovni uporabi enakega zdravila ali drugega difosfonata.
A subset of myeloid derived suppressor cells (CD38+MDSCs), regulatory T cells (CD38+Tregs) and B cells (CD38+Bregs) are susceptible to daratumumab mediated cell lysis.
Na z daratumumabom povzročeno citolizo so občutljive tudi podskupine mieloidnih supresorskih celic (CD38+MDSC), regulatornih limfocitov T (Treg) in limfocitov B (CD38+Breg).
A subset of these patients continued open- label treatment with Kineret for up to 1 year in a companion extension study.
Podskupina teh bolnikov je imela nadaljnje odprto zdravljenje z zdravilom Kineret še do enega leta v spremljevalni podaljšani študiji.
A subset of these patients continued open- label treatment with Kineret for up to 1 year in a companion extension study.
Podskupina teh bolnikov je nadaljevala odprto zdravljenje z zdravilom Kineret še do enega leta v spremljevalni podaljšani študiji.
A subset of women (N=776) vaccinated in study 001 was followed in study 007 up to 6.4 years (approximately 77 months) after the first dose (mean follow-up of 5.9 years).
Podskupino v študiji 001 cepljenih žensk (N = 776) so v študiji 007 spremljali še do 6,4 let (približno 77 mesecev) po cepljenju s prvim odmerkom (srednji čas spremljanja 5,9 let).
A sudden decrease or loss of vision - this occurs rarely
Nenadno poslabšanje ali izguba vida - to se zgodi redko
A sudden decrease or loss of vision - this occurs rarely.
Nenadno poslabšanje ali izguba vida – to se zgodi redko.
A sudden drop in blood pressure or heart rate, with or without symptomatic hypotension or bradycardia
nenaden padec krvnega tlaka ali srčne frekvence, z ali brez simptomatske hipotenzije ali bradikardije
A sudden fall in blood pressure and, in isolated cases, anaphylactic shock (which symptoms or signs are rash, hypotension, palpitation, wheezing, coughing, sneezing and difficulty breathing among others), even if you have shown no hypersensitivity to previous administration.
Nenaden padec krvnega tlaka, v posameznih primerih pa anafilaktični šok (simptomi ali znaki so lahko med drugim izpuščaj, hipotenzija, palpitacije, sopenje, kašljanje, kihanje in težave z dihanjem), četudi pri predhodni uporabi niste imeli znakov preobčutljivosti.
A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk.
Nenadna prekinitev lahko povzroči razvoj malignega nevroleptičnega sindroma, ki lahko pomeni večje tveganje za zdravje.
A sudden stop could cause you to develop a medicinal condition called neuroleptic malignant syndrome which may represent a major health risk.
Nenadna prekinitev lahko povzroči razvoj bolezenskega stanja, imenovanega nevroleptični maligni sindrom, ki lahko predstavlja večjo nevarnost za zdravje.
A sufficient quantity of sodium chloride 9 mg/mL (0.9 %) solution for injection should be added to the container to make the total volume 250 mL.
Vanj je treba dodati zadostno količino 9 mg/ml (0,9-odstotne) raztopine natrijevega klorida za injiciranje, da dosežete skupno prostornino 250 ml.
A suitable injection syringe should be used to withdraw the calculated volume of the concentrate from the vial(s).
Za izvlek izračunanega volumna koncentrata iz vial(e) je treba uporabiti primerno injekcijsko brizgo.
A suitably sensitive clinical model should be selected in which to evaluate the above risks.
Za ocenitev zgoraj navedenih tveganj je treba izbrati primerno občutljiv klinični model.
a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
sulfonilsečnino in z metforminom, če urejenost glikemije z dieto in s telesno aktivnostjo ter z dvojnim zdravljenjem s tema zdraviloma ni zadostna.
a sulphonylurea and one of the components of Qtern;
s sulfonilsečnino in eno od učinkovin v zdravilu Qtern;
a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
sulfonilsečnino, če urejenost glikemije z dieto in s telesno aktivnostjo ter z zdravljenjem z največjim toleriranim odmerkom sulfonilsečnine same ni zadostna, zdravljenje z metforminom pa zaradi kontraindikacij ali intolerance ni primerno.
a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance, a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.
sulfonilureo pri bolnikih s slabo urejeno sladkorno boleznijo kljub zdravljenju s sulfonilureo v največjih odmerkih, ki jih bolnik še prenaša, pri tem pa zdravljenje z metforminom za te bolnike ni primerno zaradi neprenašanja ali kontraindikacij;
a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea
sulfonilsečnino, samo pri bolniki, ki kažejo intolerance na metformin ali pri katerih je metformin kontraindiciran, z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku monoterapije s sulfonilsečnino.
a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.
sulfonilsečnino, le pri odraslih bolnikih, ki ne prenašajo metformina ali je metformin pri njih kontraindiciran, z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku monoterapije s sulfonilsečnino.
a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.
sulfonilsečnino, le pri odraslih bolnikih, ki ne prenašajo metformina ali je metformin pri njih kontraindiciran, z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku sulfonilsečnine v monoterapiji.
a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
sulfonilsečnino, le pri odraslih bolnikih, ki ne prenašajo metformina ali je metformin pri njih kontraindiciran, z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku monoterapije s sulfonilsečnino.
a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite monotherapy with a sulphonylurea
sulfonilsečnino, vendar le pri bolnikih z intoleranco za metformin ali bolnikih pri katerih je metformin kontraindiciran in pri katerih je urejenost glikemije nezadostna kljub zdravljenju s sulfonilsečnino samo.
a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate.
sulfonilsečnino, kadar sulfonilsečnina sama, z dieto in telesno dejavnostjo ne zagotovi ustrezne urejenosti glikemije, uporaba metformina pa za bolnika ni primerna.
A summary of action as a function of the test results during treatment with Zinbryta is presented in table 1 below.
V spodnji preglednici 1 je povzetek ukrepov, potrebnih pri rezultatih testov med zdravljenjem z zdravilom Zinbryta.
A summary of efficacy endpoints and overall survival data is provided in Table 4.
Povzetek opazovanih dogodkov učinkovitosti in podatkov o celokupnem preživetju je prikazan v preglednici 4. .
A summary of the primary and secondary endpoints is shown in Table 1.
Povzetek primarnih in sekundarnih opazovanih dogodkov je prikazan v Preglednici 1.
A supplementary analysis evaluated a hard endpoint of the percentage of patients achieving ≥3 complete RFBMs per week and an increase of ≥1 complete RFBMs per week in at least 3 of the 4 treatment weeks.
V dopolnilni analizi so ocenili odstotek bolnikov, ki so dosegli ≥ 3 celovita iztrebljanji brez rešilnega odvajala na teden, in povečanje za ≥ 1 celovito iztrebljanje brez rešilnega odvajala na teden v vsaj 3 ali 4 tednih zdravljenja.
A supplementary analysis evaluated a hard endpoint of the percentage of patients achieving ≥3 complete RFBS per week and an increase of ≥1 complete RFBMs per week in at least 3 of the 4 treatment weeks.
V dopolnilni analizi so ocenili odstotek bolnikov, ki so dosegli ≥ 3 celovita iztrebljanji brez rešilnega odvajala na teden, in povečanje za ≥ 1 celovito iztrebljanje brez rešilnega odvajala na teden v vsaj 3 ali 4 tednih zdravljenja.
A supplementary analysis evaluated the percentage of patients achieving ≥3 complete RFBMs per week and an increase of ≥1 complete RFBMs per week in at least 3 of the 4 treatment weeks.
V dopolnilni analizi so ocenili odstotek bolnikov, ki so dosegli ≥ 3 celovita iztrebljanji brez rešilnega odvajala na teden, in povečanje za ≥ 1 celovito iztrebljanje brez rešilnega odvajala na teden v vsaj 3 ali 4 tednih zdravljenja.
A supportive phase 2, open-label, multi-center study evaluated the efficacy and safety of single-agent sunitinib 50 mg daily on Schedule 4/2 [4 weeks on treatment, 2-week rest period] in patients with unresectable pNET.
Pri bolnikih z neizrezljivim pNET so opravili podporno, odprto, multicentrično študijo 2. faze za oceno učinkovitosti in varnosti samostojno uporabljanega zdravila sunitinib v odmerku 50 mg na dan po shemi 4/2 [4 tedni zdravljenja, 2 tedna premora].
A supportive study provided information on the use of Invega in adolescents over up to 2 years.
S podporno študijo so pridobili informacije o uporabi zdravila Invega pri mladostnikih v obdobju dveh let.
A survival benefit was also demonstrated in patients that had not achieved a complete/partial response following azacitidine treatment.
Primarni cilj študije je bilo celokupno preživetje.
A survival update analysis conducted with a median follow-up time of 41.6 months no longer showed a statistically significant difference although always in favour of the TCF regimen and showed that the benefit of TCF over CF is clearly observed between 18 and 30 months of follow up.
Ponovna analiza preživetja, narejena pri srednjem času spremljanja 41,6 meseca, ni več pokazala statistično značilne razlike, čeprav je bil režim s TCF še vedno ugodnejši; pokazala pa je, da so koristi TCF v primerjavi s CF jasno opazne med 18. in 30. mesecem spremljanja.
A sustained haemoglobin level of greater than 12 g/dl (7.5 mmol/l) should be avoided.
Treba se je izogobati stalnim koncentracijam hemoglobina nad 12 g/dl (7,5 mmol/l).
A swelling at the back of the eye (due to increased pressure within the brain) may be observed by a doctor or optician during INCRELEX treatment.
Med zdravljenjem z zdravilom INCRELEX lahko zdravnik ali okulist opazi oteklino očesnega ozadja (zaradi povečanega pritiska v možganih).
a swelling of the face, lips, tongue or other part of your body
zatekanje obraza, ustnic, jezika ali drugih delov telesa
a swelling of the throat, tongue or other part of your body
otekanje grla, jezika ali drugega dela telesa,
A switch to a suitable alternative antihypertensive treatment should be carried out in advance of a planned pregnancy since Rasilamlo should not be used in women planning to become pregnant.
Pred načrtovanjem nosečnosti je treba preiti na ustrezno drugo antihipertenzivno zdravljenje, saj ženske, ki nameravajo zanositi, ne smejo uporabljati zdravila Rasilamlo.
A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy.
Pri načrtovani nosečnosti je potrebno še pred zanositvijo uvesti ustrezno alternativno zdravilo.
A switch to oral administration is recommended as soon as the patients’ condition allows (see section 4.4).
Prehod na peroralno uporabo je priporočljiv takoj, ko to dopušča bolnikovo stanje (glejte poglavje 4.4).
A symptomatic treatment should be rapidly implemented and clinical monitoring should be maintained until symptoms resolve.
Potrebno je hitro simptomatsko zdravljenje in treba je vzdrževati klinični nadzor, dokler dokler simptomi niso odpravljeni. .
A symptomatic treatment should be rapidly implemented and clinical monitoring should be maintained until symptoms resolve.
Potrebno je hitro simptomatsko zdravljenje in treba je vzdrževati klinično spremljanje, dokler simptomi ne izginejo. .
A syndrome called cholinergic syndrome with sweating, salivation and abdominal cramping
indrom, imenovan holinergični sindrom, ki vključuje znojenje, slinjenje in trebušne krče,
A syringe must never be used to withdraw Toujeo from the cartridge of the SoloStar pre-filled pen or severe overdose can result (see section 4.2).
Zdravila Toujeo se iz vložka napolnjenega injekcijskega peresnika SoloStar ne sme izvleči v injekcijsko brizgo, sicer lahko pride do hudega prevelikega odmerjanja (glejte poglavje 4.2).
a syringe with an attached needle for subcutaneous injection; a cleansing swab.
brizgo za subkutano injiciranje s pritrjeno iglo, čistilni tampon.
A tablet form of 6–mercaptopurine is also available.
6-merkaptopurin je na voljo tudi v obliki tablet.
A tear or abnormal connection of the tissue in your digestive system; symptoms can include severe or persistent stomach ache
raztrganje ali nenormalne povezave tkiva v prebavilih; simptomi lahko vključujejo hude ali trdovratne bolečine v trebuhu
A temporarily diminished increase in body weight and a slight temporary reduction in the total leukocyte count was observed in dogs which were treated with pegapargase 1200 U/kg weekly for 2 weeks.
Pri psih, ki so prejemali pegaspargazo 1.200 e./kg enkrat tedensko 2 tedna, so ugotovili začasno zmanjšanje prirasta telesne mase in začasno rahlo znižanje skupnega števila levkocitov.
A temporary clumping or spiking of the hair may also be seen at the application site after treatment.
Na mestu nanosa se lahko po zdravljenju pojavi začasna zlepljenost dlake.
A temporary clumping or spiking of the hair may be seen at the application site after treatment.
Na mestu nanosa se lahko pojavi začasna zlepljenost dlake.
a temporary inflammation of the nerves that cause pain, weakness, and paralysis in the extremities; a condition in which the muscles become weak and tire easily a hole in the small intestines
začasno vnetje živcev, ki povzroča bolečino, šibkost in paralizo v okončinah, stanje, ko mišice postanejo šibke in se zlahka utrudijo luknja v tankem črevesu
A temporary small (< 2 cm) nodule may appear at the site of injection which regresses within 1 to 4 weeks
Na mestu injiciranja se lahko pojavi manjši vozlič (<2cm), ki je prehoden in izgine v enem do štirih tednih.
A temporary small (< 2 cm) nodule may appear at the site of injection which regresses within 1 to 4 weeks.
Na mestu injiciranja se lahko pojavi manjši vozlič (< 2cm), ki je prehoden in izgine v enem do štirih tednih
A temporary small nodule (hard swelling) may appear at the site of injection.
Prehodni manjši vozli (trde otekline) se lahko pojavijo na mestu injiciranja.
A temporary suspension of fluvastatin and pitavastatin
Med zdravljenjem z
A tendency towards increased risk estimates for all- cause mortality, cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed (see sections 4.2 and 4.4).
Opazili so težnjo k povišanju ocene tveganja za splošno umrljivost, srčnožilne in možganskožilne dogodke, povezane z večjimi kumulativnimi odmerki zdravil za stimulacijo eritropoeze neodvisno od prisotnosti sladkorne bolezni ali zdravljenja z dializo (glejte poglavji 4.2 in 4.4).
A tendency towards increased risk estimates for all-cause mortality, cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed (see section 4.2 and section 4.4).
Opazili so tendenco proti povečani oceni tveganja za umrljivost zaradi vseh razlogov, kardiovaskularne in cerebrovaskularne dogodke, povezane z višjimi kumulativnimi odmerki ESA, neodvisno od sladkorne boleznij ali stanja dialize (glejte poglavje 4.2 in poglavje 4.4).
A tendency towards increased risk estimates for all-cause mortality, cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed (see section 4.2 and section 4.4).
Opazili so težnjo k povišanju ocene tveganja za splošno umrljivost, srčnožilne in možganskožilne dogodke, povezane z večjimi kumulativnimi odmerki zdravil za stimulacijo eritropoeze neodvisno od prisotnosti sladkorne bolezni ali zdravljenja z dializo (glejte poglavji 4.2 in 4.4).
A tendency was observed for infantile-onset patients treated with a higher dose (40 mg/kg) to develop higher titres of IgG antibodies.
Pri bolnikih z zgodnjim nastopom bolezni, zdravljenih z višjim odmerkom (40 mg/kg), je bilo opaziti razvoj višjih titrov protiteles IgG.
a Term(s) included based on postmarketing experience.
a Neželeni učinki so vključeni na podlagi izkušenj v obdobju trženja.
A test is used to determine whether you have BRCA-mutated cancer.
Za ugotavljanje tega, ali imate raka z mutacijo gena BRCA, se uporablja posebna preiskava.
A test of thyroid function, such as thyroid stimulating hormone level (prior to treatment initiation and every 3 months thereafter)
Preiskava delovanja ščitnice, kot je določanje ravni tirotropina (pred uvedbo zdravljenja in nato vsake 3 mesece)
A test set contains 1 jar with the additional components:
Testni komplet vsebuje 1 lonček skupaj z dodatnimi sestavinami: